S
ex is an important determinant of cardiovascular structure and function, with attendant implications for phenotypes of coronary disease and heart failure. Women are less likely to develop heart failure with reduced ejection fraction, 1 however, they are overrepresented amongst patients with heart failure with preserved ejection fraction (HFpEF). 2 Postulated mediators of the sex difference in cardiovascular pathology include differences in cardiac remodeling, with prominent concentric rather than eccentric remodeling 3 and less apoptosis in response to myocardial injury. 4 There are also considerable differences in the relative impact of risk factors for cardiovascular disease in men and women; diabetes mellitus increases heart failure risk 5-fold in women compared with 2.4-fold in men, 5 and obesity has a greater impact on diastolic function in women. 6 There are substantial differences in the epidemiology and impact of hypertension across sexes. While women have a lower prevalence of hypertension during childbearing years, this rises substantially after menopause and surpasses that of men. 7 With aging, metrics of vascular stiffening, including arterial elastance calculated from echocardiography, 8 compliance derived from tonometry, 9 and pulse wave velocity, 10 are higher in women. The effect of vascular stiffening also has a greater impact on left ventricular elastance in women than men, 8 which may explain poorer diastolic function with aging. Women have higher augmentation indices between their peripheral and central pressures, 11 a contributor to the impact of hypertension on ventricular stiffness and the development of HFpEF. 12 Greater pulse pressure in women with aging 8 causes a lower coronary perfusion pressure, leading to ischemia in the setting of preexisting coronary disease including coronary microvascular disease, which is more common in women. 13 Thus vascular stiffness with aging is more prominent, and may have greater adverse impact, in women.
Previous studies of HFpEF have demonstrated higher arterial stiffness in women, accompanied by greater left ventricular systolic and diastolic stiffening, however, longterm outcomes have not been evaluated. 14 We sought to characterize sex differences in arterial and ventricular mechanics, and their impact on outcomes, in a large and well-characterized cohort of HFpEF patients.
Methods Study Design and Participants
The TOPCAT trial 15 studied the utility of spironolactone for the treatment of patients with HFpEF. The inclusion and exclusion criteria have been published previously. 15 In brief HFpEF was defined as defined as symptoms of heart failure in the setting of an ejection fraction (EF) ≥45%. Subjects aged >50 years were recruited on the basis of a previous hospitalization for heart failure or elevated natriuretic peptide levels. Exclusion criteria included uncontrolled hypertension, stage 4 to 5 renal failure, elevated serum potassium, or other significant comorbid conditions limiting life expectancy to <3 years. Because of previously published data on regional heterogeneity, 16 we studied subjects from the Americas cohort only. All participants in the TOPCAT trial gave informed consent, and ethics approval for this analysis of the TOPCAT data was obtained from the local human research ethics committee.
Echocardiographic and Hemodynamic Measurements
An echocardiographic sub-study was performed within the TOPCAT cohort, comprising 654 patients from the Americas. 17 Transthoracic echocardiography studies followed a protocol that reflected standard clinical echocardiography assessments. Baseline studies only were analyzed to compare raw differences between men and women. Pulse pressure (PP) was calculated as the difference between systolic blood pressure (SBP) and diastolic blood pressure. Left ventricular wall stress was calculated according to the invasively validated Meridional method, 18 in women, LVMI ≥115 g/m 2 in men), concentric remodeling was defined as a left ventricular mass/LVEDV ratio ≥1.5; eccentric remodeling was defined as a ratio ≤1.5.
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Primary Outcome
The primary outcome for this study was to examine the differences between men and women in comorbidities, echocardiographic parameters, and outcome defined as a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.
Statistical Analysis
Normally distributed data are presented as meanAESD and non-parametric data as median (interquartile range). Baseline
Clinical Perspective
What Is New?
• Women with heart failure with preserved ejection fraction (HFpEF) have better overall survival than men with HFpEF, however the factors influencing hospitalization and survival in HFpEF differ between the sexes; in women, pulse pressure is an important determinant of outcome whereas in men, heart rate and B-type natriuretic peptide are significant.
• Women had greater arterial and ventricular elastance and poorer ventricular-vascular coupling than men, echoing findings in elderly populations without heart failure and indicating that this enhanced vascular stiffness with aging may be a key component of the underlying pathophysiology of HFpEF in women and could be responsible for the overrepresentation of women in the HFpEF population.
What Are the Clinical Implications?
• Echocardiography revealed substantial differences between the sexes, detailed in Table 2 . Women had a significantly higher EF than men, accompanied by more negative global longitudinal strain and higher right ventricular fractional area change, as well as higher tricuspid regurgitation velocities. Men had a greater left ventricular mass index, relative wall thickness, and end systolic and diastolic volumes. However, the proportion of patients meeting sex-specific criteria for moderate or severely abnormal ventricular end-diastolic and end-systolic volumes according to American Society of Echocardiography criteria 25 was higher in women than men (9% versus 2%, P=0.002 for LVEDV; 27% versus 9%, P<0.001 for left ventricular end systolic volume). There was no difference in the proportion with eccentric or concentric remodeling in those with increased LVMI. The proportion with abnormal relative wall thickness was similar in women and men (80% men versus 77% women, P=0.44). Women had lower cardiac output and index. Left ventricular wall stress did not differ between sexes. Indices of vascular and ventricular elastance were consistently higher in women, with a lower Ea/Ees ratio in women suggestive of poorer ventricular-vascular coupling. These findings persisted after indexing Ea, Ed, and Ees to body surface area.
Outcomes
Survival analyses for time to primary end point revealed significantly better overall survival in women than men (hazard ratio [HR] 0.74, 95% CI 0.57-0.98, P=0.034), depicted in Figure 1 . In a multivariate Cox proportional hazards analysis incorporating comorbidities that differed between the sexes, sex was no longer a significant predictor of time to primary end point. In a multivariate Cox analysis incorporating comorbidities, BNP, and echocardiographic parameters that differed between men and women, global longitudinal strain (HR remained independent predictors of primary outcome. When considering factors affecting achievement of the primary end point in men and women separately, there were different predictors of outcome, depicted in Table 3 . None of the calculated variables of wall stress or elastance were predictors of outcome in men or women. 
Discussion
In this study, we examined sex differences in echocardiographic parameters and measures of arterial and ventricular stiffness in patients with HFpEF, and studied their association with long-term outcomes. Overall women were less likely to meet the primary end point than men, however PP had a greater impact. Women had greater arterial and ventricular elastance and poorer ventricular-vascular coupling. Women also had a higher ejection fraction, more negative global longitudinal strain, and better right ventricular systolic function, but a greater proportion with elevated ventricular volumes according to sex-specific criteria, lower stroke volume and lower cardiac index. Greater arterial stiffness with aging has been well established in women without HFpEF. Redfield and colleagues demonstrated higher arterial elastance and PP in women than men, with a steeper age-arterial elastance association in women, regardless of the presence of cardiovascular disease. 8 These findings are consistent with a study in a younger cohort of patients with brachial blood pressure, PWV and Similarly, arterial stiffness and wave reflection were demonstrated to be greater in women than men in a large community study. 9 Vascular stiffness is closely related to the development of HFpEF. Lam and colleagues performed an analysis of the Olmsted County community cohort of patients with HFpEF or hypertension without heart failure, and controls with echocardiographically derived ventricular-vascular function. Arterial elastance and PP were higher in patients with HFpEF and hypertension, as was Ees. 26 Kawaguchi et al used pressure-volume loops to assess ventricular-vascular stiffening in patients with HFpEF and controls with hypertension, finding that Ees and Ea were substantially higher in patients with HFpEF compared with hypertensive controls. 27 Desai and colleagues performed echocardiography and tonometry on HFpEF patients, hypertensives and controls, and found increased central aortic stiffness in hypertensives and HFpEF patients. Importantly, carotid-femoral pulse wave velocity was markedly higher in HFpEF patients compared with hypertensives and controls; persisting after adjusting for BMI, SBP, and renal function, and correlating with left ventricular mass index and BNP. 28 Taken together, these studies underscore the importance of vascular stiffness, particularly of the central vasculature, in the pathogenesis of HFpEF.
That sex differences in indices of arterial stiffness persist amongst patients with HFpEF is of interest, therefore, as it could be expected that men with HFpEF have a degree of vascular and ventricular stiffness similar to that of women given its role in the pathophysiology of HFpEF. However, women are more sensitive to the effects of vascular stiffening. Redfield et al established that the greater arterial elastance resulted in worse ventricular-vascular coupling and worse diastolic function in women than men. 8 Furthermore, women have a greater degree of left ventricular remodeling, based on LVMI and relative wall thickness, in response to hypertension than men. 3 Gori and colleagues analyzed patients in the PARAMOUNT (Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction) study of an angiotensin receptor neprilysin inhibitor versus angiotensin receptor blocker in patients with HFpEF according to sex, a study including 279 participants. 14 They found that women had higher arterial elastance and were far more likely to have concentric and eccentric remodeling than men in the PARAMOUNT study. 14 We did not demonstrate similar sex differences in the proportion of patients with elevated LVMI, or eccentric or concentric remodeling, in this larger cohort. However, the LVMI was considerably lower in both men and women in the aforementioned study, which may suggest that the TOPCAT trial incorporated a population with more advanced ventricular modeling, blunting the sex differences. Importantly, in the current analysis of the TOPCAT trial, arterial stiffness as indicated by PP was an independent predictor of achievement of the primary outcome in women, but not men. This reinforces the notion that ventricularvascular stiffening plays a greater role in HFpEF pathophysiology and severity in women than men, in whom other mechanisms are more active. There is mounting evidence in the literature regarding the clinical significance of PP in determining the prognosis of cardiovascular conditions. A recent analysis of the TOPCAT trial indicated that low diastolic blood pressure is associated with greater adverse outcomes in HFpEF patients. 29 Higher PP is also associated with a greater burden of coronary disease and increased mortality after percutaneous coronary intervention compared with those with narrow PP. 30 These associations could be explained by subclinical myocardial ischemia attributable to the combination of increased myocardial oxygen demand and systemic hypertension, in concert with lower diastolic coronary perfusion pressure. 31 In women, a higher prevalence of coronary microvascular disease 13 may render them more susceptible to these reductions in coronary perfusion, and could help to explain the greater impact of increasing PP on primary outcome. Achievement of the primary outcome was higher in men than women, with poor outcomes driven most strongly by heart rate and BNP in men. This is consistent with a study of 260 patients with HFpEF finding that men were more likely to die of cardiovascular causes than women, and tended to achieve the combined end point of cardiac death or heart failure hospitalization at greater rates. 32 Likewise, Lam et al analyzed the I-PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction) trial of irbesartan in HFpEF (EF ≥45%) with regard to sex differences in survival, and found that women had a 21% lower risk of all-cause events than men, which persisted after adjusting for differences in baseline characteristics. In analyses investigating sex differences in predictors of all-cause events, comorbidities played an important role in distinguishing predictors between men and women; for example, smoking and a history of coronary revascularization were predictive of poor outcome in men. 24 Often poorer survival in men has been attributed to higher rates of ischemic heart disease, which drives adverse outcomes across all phenotypes of heart failure. 33 A history of myocardial infarction or angina did not predict outcome in our analysis despite being more common in men, however, this may have been because of lack of statistical power. An important predictor of outcome in HFpEF is natriuretic peptide level. A key study of heart failure patients in Singapore and New Zealand found that while overall HFpEF patients had lower mortality than heart failure with reduced ejection fraction patients, stratifying according to NT-proBNP quartile overrode the differences in prognosis according to heart failure phenotype. 34 BNP and NT-proBNP are released in response to myocardial wall stress, 35 and in HFpEF this is driven by increased relative wall thickness attributable to myocardial remodeling, and afterload. However, there are other active contributors to natriuretic peptide levels; e 0 has been associated with BNP levels even in the setting of the same left ventricular wall stress, as has s 0 which may reflect alterations to the structure of the left ventricular myocardium reflecting fibrosis and cellular hypertrophy. 35 In our analysis of the TOPCAT data, BNP levels were significantly higher in men; however, this did not persist after indexing BNP to left ventricular mass, and wall stress did not differ between men and women. Similarly, blood pressure and the proportion with abnormal relative wall thickness did not differ between men and women. BNP was an independent predictor of outcome in men but not women when considered separately, and wall stress was not a predictor of outcome in either sex. This may indicate that factors contributing to BNP release other than wall stress, afterload and myocardial wall thickness are responsible for the poorer prognosis in men with HFpEF. Another determinant of achievement of the primary outcome in men was heart rate. This finding mirrors a large study of propensity-matched subjects from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry of outcomes according to heart rate strata (<70 versus ≥70 beats/min), finding that heart rate was independently associated with allcause mortality in HFpEF patients. 36 Interestingly, when analyzing in subgroups according to sex, heart rate was clearly associated with outcome in women but not men, contrary to our findings. Thus, further investigation may help to delineate the relevance of heart rate in determining outcomes in men and women with HFpEF.
Clinical Implications
This study emphasizes sex differences in ventricular-vascular stiffening, even within the HFpEF population, by demonstrating greater indices of arterial stiffness in women with a significant impact on their achievement of the primary outcome in the TOPCAT trial.
In particular, we demonstrate that despite similar overall blood pressures, measures of vascular stiffness were more impaired in women with a greater impact on long-term outcomes. Thus, better understanding the processes that lead to increased vascular stiffness is integral to preventing HFpEF and mitigating adverse outcomes in women in particular. Given the close relationship between hypertension and vascular stiffness, aggressive blood pressure management is key in women. However, hypertension may not fully explain differences in pulsatility and arterial elastance with aging, albeit this is without taking into consideration blood pressure variability. 10 Further research will benefit from identifying mechanisms to reduce ventricular-vascular stiffening. Furthermore, these findings may suggest that sex can be used to better characterize patients with HFpEF into phenogroups with different characteristics, and for whom outcome is affected by different factors. Just as there are different mechanisms behind HFpEF which warrant divergent therapeutic approaches, 37 the relative importance of, for example, extracellular matrix involvement versus cardiomyocyte dysfunction in men and women could be further explored to better understand the molecular mechanisms behind these processes.
Limitations
This study has inherent limitations associated with being a post-hoc analysis of a previous study. Given the substantial heterogeneity between geographic regions, we selected only patients from the Americas region, significantly limiting the number of patients with echocardiographic data. This is likely to have affected our statistical power, and may have introduced confounders not adjusted for in our analysis given the more select nature of the cohort. Certainly, further statistical investigation of the interaction between sex, hemodynamics, and outcome was potentially limited by the modest sample size. Another limitation of the study is the EF cut-off of 45%; although this was the accepted definition of HFpEF at the time of trial design, the definition has since been revised to an EF ≥50%. 38 Given women have higher EFs, 39 and there are strong associations between EF and outcome in heart failure, this may have affected our results. Finally, the study is limited by its retrospective nature, and future studies could build on these results with the addition of invasive hemodynamic data including invasive measures of central arterial pressure, along with pulmonary arterial and pulmonary capillary wedge measurements.
Conclusions
This analysis reveals overall more favorable prognosis in women compared with men in the TOPCAT trial. Numerous differences in vascular function, natriuretic peptides, comorbidities, and echocardiographic parameters between men and women are active in mediating this survival benefit in women. Importantly, women have greater metrics of ventricularvascular stiffness, and arterial elastance as indicated by PP is an important predictor of outcome in women, but not men. This indicates divergent phenotypes within this selective trial population according to sex and may represent an opportunity for further research into sex-specific mechanisms and therapies for vascular stiffness with a view to preventing and treating HFpEF.
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